Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone

NCT02027961 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02027961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02027961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
December 20, 2013
Completion date
April 24, 2018
Enrollment
68 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma